BLOOMFIELD, Conn., Oct. 3, 2024 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its third quarter 2024 financial results on Thursday, October 31, 2024, and will host a conference call the same day.
Third quarter 2024 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows:
Live Call
(888) 566-1889 (Domestic)
(773) 799-3989 (International)
Passcode: 10312024
Replay
(888) 282-0035 (Domestic)
(203) 369-3602 (International)
It is strongly suggested that participants dial in to the conference call by 8:15 a.m. ET on October 31. A replay of the call will be available from 12:30 p.m. ET on October 31 until 11:59 p.m. ET on November 14, 2024. Additionally, the conference call will be available on a live internet webcast at https://investors.thecignagroup.com/events-and-presentations/default.aspx in the Investor Relations section of The Cigna Group's website. Please note that this feature will be in listen-only mode.
A copy of the company's news release and financial supplement will be available on The Cigna Group's website in the Investor Relations section at https://investors.thecignagroup.com/overview/default.aspx, no later than 6:30 a.m. ET on October 31.
About The Cigna Group
The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services marketed under Cigna Healthcare, Evernorth Health Services or its subsidiaries. The Cigna Group maintains sales capabilities in more than 30 markets and jurisdictions, and has approximately 186 million customer relationships around the world. Learn more at thecignagroup.com.
Investor Relations Contact
Ralph Giacobbe
1 (860) 787-7968
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Justine Sessions
1 (860) 810-6523
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$280.00 |
Daily Change: | -1.63 -0.58 |
Daily Volume: | 412,344 |
Market Cap: | US$77.880B |
October 31, 2024 September 12, 2024 September 12, 2024 August 01, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB